Evidence map›Paper›PMID 32823550›Full record

ArticleInternational journal of molecular sciences2020

IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.

Felipe Silva Rodrigues, Vanessa Silva Miranda, Tatiana Correa Carneiro-Lobo, Luiza Coimbra Scalabrini, Björn Kruspig, Elena Levantini, Daniel J Murphy, Daniela Sanchez Bassères

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Felipe Silva RodriguesDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-000 São Paulo, Brazil.ORCID 0000-0003-2139-8161
Vanessa Silva MirandaDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-000 São Paulo, Brazil.
Tatiana Correa Carneiro-LoboDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-000 São Paulo, Brazil.
Luiza Coimbra ScalabriniDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-000 São Paulo, Brazil.
Björn KruspigInstitute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.ORCID 0000-0002-1712-5411
Elena LevantiniBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4612-3105
Daniel J MurphyInstitute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.ORCID 0000-0002-5538-5468
Daniela Sanchez BassèresDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-000 São Paulo, Brazil.ORCID 0000-0001-7745-3567
Universidade de São Paulo · BRBeth Israel Deaconess Medical Center · USCancer Research UK Scotland Institute · GBUniversity of Glasgow · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2M
Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI DANIEL G TENEN · 2017 to 2026
$24.6M
Transgenic Mouse CoreP01CA089021 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CANTLEY, LEWIS C. · 2001 to 2011
$20.1M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
Translational studies of Hsp90 inhibitors in NSCLCP50CA090578 · NCI · DANA-FARBER CANCER INST · PI YEAP, BEOW Y · 2008 to 2012
$11.4M
SPORE in Lung CancerP20CA090578 · NCI · DANA-FARBER CANCER INSTITUTE · PI JOHNSON, BRUCE E. · 2003 to 2007
$5.1M
Determining the role of DNMT-interacting RNAs in myeloid disordersK99CA188595 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI DI RUSCIO, ANNALISA · 2014 to 2015
$219k
Cancer Research UK 27603NCI NIH HHS K99 CA188595NCI NIH HHS P01 CA066996NCI NIH HHS P01 CA089021NCI NIH HHS P20 CA090578NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA090381NCI NIH HHS P50 CA090578NCI NIH HHS P50 CA180995NHLBI NIH HHS P01 HL131477
6 · The paper itself

Abstract

KRAS oncogenic mutations are widespread in lung cancer and, because direct targeting of KRAS has proven to be challenging, KRAS-driven cancers lack effective therapies. One alternative strategy for developing KRAS targeted therapies is to identify downstream targets involved in promoting important malignant features, such as the acquisition of a cancer stem-like and metastatic phenotype. Based on previous studies showing that KRAS activates nuclear factor kappa-B (NF-κB) through inhibitor of nuclear factor kappa-B kinase β (IKKβ) to promote lung tumourigenesis, we hypothesized that inhibition of IKKβ would reduce stemness, migration and invasion of KRAS-mutant human lung cancer cells. We show that KRAS-driven lung tumoursphere-derived cells exhibit stemness features and increased IKKβ kinase activity. IKKβ targeting by different approaches reduces the expression of stemness-associated genes, tumoursphere formation, and self-renewal, and preferentially impairs the proliferation of KRAS-driven lung tumoursphere-derived cells. Moreover, we show that IKKβ targeting reduces tumour cell migration and invasion, potentially by regulating both expression and activity of matrix metalloproteinase 2 (MMP2). In conclusion, our results indicate that IKKβ is an important mediator of KRAS-induced stemness and invasive features in lung cancer, and, therefore, might constitute a promising strategy to lower recurrence rates, reduce metastatic dissemination, and improve survival of lung cancer patients with KRAS-driven disease.

Indexed as

Cell MovementAdenocarcinoma of LungCell Line, TumorCell ProliferationCell Self RenewalGene Expression Regulation, NeoplasticHumansI-kappa B KinaseLung NeoplasmsMutationNeoplasm InvasivenessNeoplastic Stem CellsProto-Oncogene Proteins p21(ras)RNA, Small InterferingSpheroids, CellularI-kappa B KinaseKRAS protein, humanProto-Oncogene Proteins p21(ras)RNA, Small Interferingcancer stem cellsIKKβ kinaseinvasionKRASlung cancermigrationNF-κB signallingstemness

Identifiers

PMID32823550
PMCPMC7460870
OpenAlexW3048893595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.